Time Off For Bad Behavior
- The Martha And Sam Show. // njbiz;6/17/2002, Vol. 15 Issue 25, p3
Reports on the arrest of Samuel Waksal, former chief executive officer of ImClone Systems, for insider trading charges. Reason for the charges; Number of shares sold by members of Waksal family.
- ImClone Exec Said To Defraud B of A of $44M. Boraks, David // American Banker;8/12/2002, Vol. 167 Issue 153, p24
Cites a U.S. government allegation that Samuel D. Waksal, former chief executive officer of biotechnology firm ImClone Systems Inc., committed fraud in obtaining a personal loan from Bank of America Corp. Alleged forging by Waksal of the signature of ImClone's corporate lawyer on documents...
- ImClone Chief Steps Down Amid Controversy. // Chemical Market Reporter;5/27/2002, Vol. 261 Issue 21, p3
Reports on the resignation of Samuel Waksal as president and chief executive of ImClone Systems Inc. in the U.S. Impact of the refusal of the U.S. Food and Drug Administration to accept the filing for the Erbitux drug, on the stocks of the company; Plan of ImClone to conduct clinical trials for...
- Insider trading is not a good thing. Mannix, Margaret // U.S. News & World Report;6/24/2002, Vol. 132 Issue 22, p37
Discusses the arrest of Samuel Waksal, former chief executive officer (CEO) of biotechnology firm ImClone Systems, on criminal and civil charges of illegal insider trading. Allegation that Waksal tried to sell $5 million worth of ImClone stock after he learned that the U.S. Food and Drug...
- WEEK IN REVIEW. // Crain's New York Business;6/16/2003, Vol. 19 Issue 24, p42
Samuel Waksal, founder and ousted CEO of ImClone Systems Inc., a company that researches and develops therapeutics for treatment of cancer, was sentenced to 87 months in prison and ordered to pay $3 million in fines for insider trading and tax evasion, and another $1.26 million in restitution....
- A battle royal in biotech. Sherrid, Pamela // U.S. News & World Report;2/18/2002, Vol. 132 Issue 5, p34
Discusses a dispute over a proposal by Bristol-Myers Squibb to take over the development of Erbitux, a cancer drug, from ImClone Systems. Why ImClone's managers, Samuel and Harlan Waksal, seem prepared to reject Bristol-Myers' plan; Implications for the pharmaceutical and biotechnology...
- Copping a plea. Stein, Lisa // U.S. News & World Report;10/28/2002, Vol. 133 Issue 16, p16
Profiles ImClone Systems chief executive officer Sam Waksal. His plea of guilt to six counts of fraud; Admittance of telling family members to sell ImClone stock prior to its fall; Rejection of its colon cancer drug by the U.S. Food and Drug Administration.
- Will She Walk? Freedman, Michael; Lambert, Emily; Flannery, Russell // Forbes Global;7/7/2003, Vol. 6 Issue 14, p20
Discusses the federal criminal case and civil suit filed against Martha Stewart for the insider trading of ImClone stocks. Details of the case; Sentence given to ImClone founder Samuel Waksal; Definition of insider trading.
- TARNISH, ANYONE? // People;7/8/2002, Vol. 58 Issue 2, p44
Reports on the allegations of insider trading facing Martha Stewart. Details of the investigation, revolving around the timing of her sale of nearly 4,000 shares of ImClone, a biotechnology company; Charges facing ImClone chief executive officer Dr. Sam Waksal; Speculation regarding Peter...